Details for New Drug Application (NDA): 216728
✉ Email this page to a colleague
The generic ingredient in SIROLIMUS is sirolimus. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
Pharmacology for NDA: 216728
Mechanism of Action | Protein Kinase Inhibitors mTOR Inhibitors |
Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 216728
Suppliers and Packaging for NDA: 216728
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SIROLIMUS | sirolimus | SOLUTION;ORAL | 216728 | ANDA | Novadoz Pharmaceuticals LLC | 72205-099 | 72205-099-78 | 1 BOTTLE, GLASS in 1 CARTON (72205-099-78) / 60 mL in 1 BOTTLE, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
Approval Date: | Jan 19, 2023 | TE: | AA | RLD: | No |
Complete Access Available with Subscription